Log in

NYSE:ZYMEZymeworks Stock Price, Forecast & News

$33.19
-1.90 (-5.41 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$33.16
Now: $33.19
$35.06
50-Day Range
$34.18
MA: $36.81
$40.00
52-Week Range
$20.33
Now: $33.19
$52.75
Volume779,500 shs
Average Volume412,461 shs
Market Capitalization$1.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More
Zymeworks logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.54 million
Book Value$6.24 per share

Profitability

Net Income$-145,440,000.00
Net Margins-629.37%

Miscellaneous

Employees180
Market Cap$1.51 billion
Next Earnings Date8/7/2020 (Estimated)
OptionableOptionable

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Zymeworks (NYSE:ZYME) Frequently Asked Questions

How has Zymeworks' stock been impacted by COVID-19 (Coronavirus)?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZYME stock has increased by 2.9% and is now trading at $33.19. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zymeworks?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zymeworks.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Zymeworks.

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) released its earnings results on Thursday, May, 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.51. The company earned $8.27 million during the quarter, compared to analyst estimates of $7.78 million. Zymeworks had a negative net margin of 629.37% and a negative return on equity of 46.17%. View Zymeworks' earnings history.

What price target have analysts set for ZYME?

12 analysts have issued twelve-month price objectives for Zymeworks' shares. Their forecasts range from $23.00 to $70.00. On average, they expect Zymeworks' stock price to reach $50.18 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price. View analysts' price targets for Zymeworks.

Has Zymeworks been receiving favorable news coverage?

Media stories about ZYME stock have been trending somewhat negative on Saturday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zymeworks earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Zymeworks.

Are investors shorting Zymeworks?

Zymeworks saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,860,000 shares, an increase of 59.0% from the June 15th total of 1,170,000 shares. Based on an average trading volume of 430,600 shares, the short-interest ratio is presently 4.3 days. Approximately 4.8% of the company's shares are sold short. View Zymeworks' Current Options Chain.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Just Energy Group (JE), Just Energy Group (JE), Gilead Sciences (GILD), Cronos Group (CRON), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), AbbVie (ABBV) and Aurora Cannabis (ACB).

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Exane Derivatives (0.01%) and Contravisory Investment Management Inc. (0.00%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly, Neil A Klompas and Troy Cox. View institutional ownership trends for Zymeworks.

Which institutional investors are buying Zymeworks stock?

ZYME stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives, and Contravisory Investment Management Inc.. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox. View insider buying and selling activity for Zymeworks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $33.19.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $1.51 billion and generates $29.54 million in revenue each year. The company earns $-145,440,000.00 in net income (profit) each year or ($3.83) on an earnings per share basis. Zymeworks employs 180 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.